An Innovative Pipeline Integrating Mendelian Randomization for Personalized Disease Risk Assessment and Therapeutic Drug Identification
ISEF · 2024 Computational Biology and Bioinformatics
Overview
Disease pathogenesis is closely associated with genetically influenced metabolites. The identification of individualized metabolite-disease associations is crucial in advancing personalized treatments. Mendelian Randomization (MR) is a modern biostatistical approach utilizing genetic variants (SNPs) linked to a modifiable exposure to estimate its causal relationship with an outcome, providing unbiased, time-efficient, and cost-effective results. In this study, Two-Sample MR was employed to identify causal relationships between human serum metabolites and 10 prevalent diseases, yielding 262 metabolite-disease associations. Utilizing MR results, the SNPs with the greatest impacts on the metabolite-disease associations were defined as TOP SNPs. Input whole genome sequence data was analyzed, and a TOP SNP based regression analysis was performed to determine disease risk. Furthermore, drug repositioning and discovery were used to offer personalized therapeutic intervention strategies based on the individual’s genomic profile. Drug repositioning was automated using Pharos; FDA-approved drugs targeting eight metabolites were identified to be used in the risk reduction of seven diseases. Additionally, blind docking and sequence-based deep learning were used in tandem for custom drug discovery. Three potential drug compounds (PubChem IDs 849659, 847243, 846402) were identified to adjust levels of metabolites arachidonate, bilirubin and mannose aiming to mitigate risk in six diseases. This end-to-end process was implemented on a user-friendly web-UI for efficient use. This novel pipeline will be used to identify targetable causal metabolite-disease associations, make personalized risk assessments, and provide custom drug repositioning and discovery options for risk reduction.
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2019
A Secure Implementation of Mendelian Randomization via Multi-Party Computation
ISEF · 2024
Identification of Novel Target Genes and ML-Based Drug Repurposing and Discovery for Alzheimer’s Disease in the Presence of Metabolic Comorbidities
ISEF · 2021
A Novel Computational Approach to Drug Discovery Through Drug Repositioning
ISEF · 2026
A Multi-Omics and Machine Learning Approach for Identifying Potential Salivary Biomarkers of and Treating Major Depressive Disorder
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair